Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.

Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily.

Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89 billion for the quarter, above the Wall Street consensus of $4.45 billion.

Gilead said its projects total product sales between $30 billion and $31 billion this year, equal to what analysts were expecting, Reuters reports.

Separately, social media chatter is circulating that said Gilead Harvoni U.S. sales ($1.707 billion) missed expectations by over 20 percent, while international sales ($1.638 billion) beat by 80 percent.

These figures have not been verified by an analyst; Gilead has not yet returned a request for comment on this issue.